Analyst Price Targets — VERX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 4, 2026 1:00 pm | Lucky Schreiner | D.A. Davidson | $12.00 | $11.43 | StreetInsider | Vertex Inc. (VERX) PT Lowered to $12 at DA Davidson on Recalibrated Cloud Expectations |
| August 4, 2026 11:13 am | — | Stephens | $18.00 | $13.40 | TheFly | Vertex price target lowered to $18 from $20 at Stephens |
| August 4, 2026 10:30 am | — | Robert W. Baird | $17.00 | $13.40 | TheFly | Vertex price target lowered to $17 from $19 at Baird |
| July 21, 2026 6:04 am | Chris Quintero | Morgan Stanley | $15.00 | $12.89 | StreetInsider | Morgan Stanley Downgrades Vertex Inc. (VERX) to Equalweight |
| May 9, 2026 1:10 pm | — | Jefferies | $14.00 | $14.93 | TheFly | Vertex price target lowered to $14 from $16 at Jefferies |
| May 8, 2026 1:27 pm | Chris Quintero | Morgan Stanley | $19.00 | $14.56 | TheFly | Vertex price target raised to $19 from $18 at Morgan Stanley |
| May 8, 2026 12:42 pm | — | D.A. Davidson | $15.00 | $14.40 | TheFly | Vertex price target raised to $15 from $13 at DA Davidson |
| May 7, 2026 10:09 pm | Adam Hotchkiss | Goldman Sachs | $21.00 | $14.67 | TheFly | Vertex price target lowered to $21 from $23 at Goldman Sachs |
| April 30, 2026 4:48 pm | — | Morgan Stanley | $18.00 | $12.23 | TheFly | Vertex price target lowered to $18 from $20 at Morgan Stanley |
| February 12, 2026 1:52 pm | — | D.A. Davidson | $13.00 | $12.32 | TheFly | Vertex price target lowered to $13 from $23 at DA Davidson |
Latest News for VERX
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases. Vertex also announced the expansion of its executive leadership team, in support of the…
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investor Relations and Manisha Pai, Executive Director of Investor Relations, will participate in a fireside chat at the Wells Fargo 21st Annual Healthcare Conference on Wednesday, September 9, 2026, at 4:30 p.m. EDT. Susie…
Vertex's stock is up 15% in a month as strong CF sales, rising non-CF drug revenues and renal pipeline progress boost its growth story.
Explore the exciting world of Vertex Pharmaceuticals (VRTX +1.44%) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
Vertex Pharmaceuticals' business could be in trouble if it faces competition in its core market. However, one of the company's most important potential competitors recently hit a clinical setback.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VERX.
U.S. House Trading
No House trades found for VERX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.